Literature DB >> 11237526

Mouse models for sporadic cancer.

R Meuwissen1, J Jonkers, A Berns.   

Abstract

Much of the advancement in mouse models for cancer during the past 2 decades can be attributed to our increasing capacity to specifically modify the mouse germ line. The first generations of oncomice and tumor-suppressor gene knockouts are now being succeeded by regulatable or conditional mouse tumor models, which can be utilized more effectively to establish correlations between distinct genetic lesions and specific tumor characteristics and to design and improve therapeutic intervention strategies. In this review we try to give the reader a flavor of how the latest reagents can be utilized. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11237526     DOI: 10.1006/excr.2000.5146

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  3 in total

1.  Understanding cancer: from the gene to the organism. Conference on genes and cancer.

Authors:  Iain Hagan; Andrew D Sharrocks
Journal:  EMBO Rep       Date:  2002-05       Impact factor: 8.807

2.  Clinical applications of mouse models for breast cancer engaging HER2/neu.

Authors:  Elizabeth A Fry; Pankaj Taneja; Kazushi Inoue
Journal:  Integr Cancer Sci Ther       Date:  2016-10-28

3.  Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma.

Authors:  Chun-Ming Ho; Kuen-Tyng Lin; Roger Shen; De-Leung Gu; Szu-Shuo Lee; Wen-Hui Su; Yuh-Shan Jou
Journal:  Comput Struct Biotechnol J       Date:  2022-04-09       Impact factor: 6.155

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.